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Abstract
Background: Two isoforms of the enzyme adenosine kinase (AdK), which differ at their N-terminal ends, are found
in mammalian cells. However, there is no information available regarding the unique functional aspects or
regulation of these isoforms.
Results: We show that the two AdK isoforms differ only in their first exons and the promoter regions; hence they
arise via differential splicing of their first exons with the other exons common to both isoforms. The expression of
these isoforms also varied greatly in different rat tissues and cell lines with some tissues expressing both isoforms
and others expressing only one of the isoforms. To gain insights into cellular functions of these isoforms, mutants
resistant to toxic adenosine analogs formycin A and tubercidin were selected from Chinese hamster (CH) cell lines
expressing either one or both isoforms. The AdK activity in most of these mutants was reduced to <5% of wild-
type cells and they also showed large differences in the expression of the two isoforms. Thus, the genetic
alterations in these mutants likely affected both regulatory and structural regions of AdK. We have characterized
the molecular alterations in a number of these mutants. One of these mutants lacking AdK activity was affected in
the conserved NxxE motif thereby providing evidence that this motif involved in the binding of Mg
2+ and
phosphate ions is essential for AdK function. Another mutant, Fom
R-4, exhibiting increased resistance to only C-
adenosine analogs and whose resistance was expressed dominantly in cell-hybrids contained a single mutation
leading to Ser191Phe alteration in AdK. We demonstrate that this mutation in AdK is sufficient to confer the novel
genetic and biochemical characteristics of this mutant. The unusual genetic and biochemical characteristics of the
Fom
R-4 mutant suggest that AdK in this mutant might be complexed with the enzyme AMP-kinase. Several other
AdK mutants were altered in surface residues that likely affect its binding to the adenosine analogs and its
interaction with other cellular proteins.
Conclusions: These AdK mutants provide important insights as well as novel tools for understanding the cellular
functions of the two isoforms and their regulation in mammalian cells.
Background
Adenosine kinase (AdK) is a major purine salvage path-
w a ye n z y m eb e l o n g i n gt ot h er i b o k i n a s ef a m i l yo fp r o -
teins [1-4]. It plays a central role in regulating the
intracellular and interstitial concentrations of the purine
nucleoside adenosine (Ado), which exhibits potent
cardioprotective and neuroprotective activity [5-7]. Dur-
ing ischemia, the compromised regeneration of ATP
causes an increase in the intracellular concentration of
Ado, which results in its net efflux into extracellular
space where it binds to Gi/o-coupled Ado receptors: A1,
A2A,A 2B, and A3, to modulates a variety of physiological
responses to reduce tissue damage from ischemic injury
[5,6,8-10]. The expression of AdK undergoes rapid coor-
dinated changes in the brain following epileptic seizures
or stroke, resulting in an acute surge of Ado, which
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evidence in support of the protective role of Ado has
been obtained from studies where transient down regu-
lation of AdK after acute brain injury protected brain
from seizures and cell death, whereas its overexpression
as in epilepsy caused seizure aggravation and promoted
cell death [11-13].
AdK, in addition to its central role in purine salvage
and ATP catabolism, also plays a critical role in the
maintenance of methylation reactions. In the S-adeno-
sylmethionine (SAM) dependent methylation pathway,
Ado and homocysteine (Hcy) are produced as a result
of hydrolysis of S-adenosyl-homocysteine (SAH), which
is the common end product of all methylation reactions
[1,14-17]. The hydrolysis reaction, which is catalyzed by
t h ee n z y m eS A H - h y d r o l a s e ,i sr e v e r s i b l ea n dt h ee q u i l i -
brium constant of this reaction favors SAH formation.
Hence, unless the hydrolysis product, Ado and Hcy are
rapidly removed, it will lead to the buildup of SAH,
which is a potent inhibitor of transmethylation reactions
[14,17,18]. In the guinea-pig heart, the transmethylation
pathway has been shown to be an important intracellu-
lar source of Ado under normal conditions and the Ado
produced by this mechanism is mainly salvaged by AdK
[19]. Studies with the AdK knockout mouse, which
causes liver failure and early postnatal death [16], indi-
cate that the effects of AdK deficiency on transmethyla-
tion reactions are the main underlying causes for its
lethal effect [16]. The deficiency of AdK due to its pivo-
tal role in the maintenance of transmethylation reaction
also causes developmental abnormalities and reduced
salt stress in plants [20,21].
Two isoforms of AdK are present in mammalian spe-
cies [22-25]. These isoforms differ from each other only
in their N-termini. The long isoform (AdK-L) of AdK
contains an extra 20-21 amino acids in place of the first
four amino acids of the AdK-short (AdK-S) isoform
[23,26]. Studies with the recombinant AdK-L and AdK-
S proteins have revealed no differences in their bio-
chemical or kinetic properties [23](unpublished results).
However, we recently showed that the N-terminal
extension in the AdK-L functions as a nuclear localiza-
tion signal [27]. Thus, of the two AdK isoforms, AdK-L
is targeted to the nucleus whereas AdK-S is localized in
the cytoplasm [27]. The differential subcellular localiza-
tion of these two AdK isoforms suggests that they carry
out different physiological functions. However, there is
no information available at present regarding the unique
cellular functions of these isoforms or how their expres-
sion is regulated.
Unlike the lethal phenotype of AdK
-/- mice, AdK defi-
cient mutants can be readily obtained in cultured cells
by selecting in the presence of toxic concentrations of
the Ado analogs [25,28-31]. Most of such mutants lack
AdK activity and some mutants that have been studied
in detail contained large deletions within the AdK gene
[24,32]. Our recent work shows that in contrast to the
Chinese Hamster Ovary (CHO) cells that expresses only
the AdK-L isoform, in the CH V79 cell line established
from embryonic lung [33] both AdK-L and AdK-S iso-
forms are expressed. Hence, to gain further insights into
the cellular functions of AdK, in the present work we
report the isolation and characterization of mutants
resistant to Ado analogs from V79 and other CH cell
lines. Our results show that these mutants exhibit inter-
esting differences in their cross-resistance pattern
towards the N- and C- Ado analogs and also in the
expression profiles of the two AdK isoforms. (Note: In
N-nucleosides the purine base is linked to ribose via a
N-C bond, whereas in C-nucleosides this linkage
involves a C-C bond [34,35]). Several of these mutants
contained novel molecular alterations in AdK affecting
its activity/function. One of these mutants that exhibited
increased resistance to only C-Ado analogs, and whose
drug-resistance phenotype was dominantly expressed in
cell hybrids formed with AdK
+ cells, has been character-
ized in detail [34]. We showed that a single point muta-
tion in AdK is responsible for its novel genetic and
biochemical characteristics. These mutants provide
important insights and novel tools for understanding the
cellular functions and regulation of the AdK isoforms in
mammalian cells.
Results
The AdK-L and AdK-S Isoforms Differ in their First Exons
and the Promoter Sequences
The AdK genes in human as well as rodent species are
unusually large (human 546 kb and mouse 390 kb) and
they consist of 11 exons that range in length from 36 to
7 6 5n t[ 3 2 , 3 6 ] .W eh a v ep r e v i o u s l ys h o w nt h a tt h ep r o -
moter for the AdK-L isoform in human, CH and other
mammals is bidirectional and it is linked in a head-to-
head fashion with the gene encoding the clathrin adap-
tor mu3A protein [36]. The first exon of the AdK-L iso-
form contains the sequence information distinguishing
it from the AdK-S isoform (Figure 1). The first exon
and the promoter for the AdK-S isoform have not yet
been identified. Our blast searches on the human gen-
ome with the nucleotide sequence specific for the AdK-
S isoform and its upstream non-coding region [37] have
revealed that it matches perfectly with a sequence within
the first intron of the AdK-L isoform. This sequence
region encodes for all amino acids that are distinctive of
the AdK-S isoform (Figure 1, lower part). The analysis
of the 3-4 kb region upstream of the AdK-S coding
sequence using the EMBOSS program [38] indicates the
presence of a promoter about 350 bp upstream of the
initiator codon. This predicted promoter is located
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binding sites are present in its proximity (Figure 1). Stu-
dies to determine the promoter activity of this region
and the significance of various regulatory elements pre-
sent in its vicinity will be undertaken in future. Because
the AdK-L and AdK-S isoforms are identical except for
the amino acids encoded by their first exons, the
observed structural organization of the AdK gene indi-
cates that the two AdK isoforms arise by differential
splicing of their unique first exons with the other AdK
exons. The fact that each of these exons has their own
promoters strongly suggests that the expression of the
Figure 1 A schematic drawing showing the genomic organization of the first exons and promoter regions for the AdK-L and AdK-S
genes in the human genome. The AdK gene (both AdK-L and AdK-S isoforms) in human is comprised of 11 exons. Except for the first exons,
all the remaining exons (not shown here) are common to these isoforms. The Exon-1 and promoter region for the AdK-L isoform were identified
in earlier work [32,36]. The intron-1 for the AdK-L is now shown to contain the first exon for the AdK-S isoform. The first exons for the AdK-L and
AdK-S isoforms encode for all the amino acids that distinguish these two isoforms. The upstream regions of both exons contain binding sites for
several transcriptional factors, only some of which are shown here. The introns and exons are not drawn to the scale in this diagram.
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transcriptional level.
Expression of the Two Isoforms Differ in Various Tissues
and Cell Lines
The expression profile of AdK in rat tissues was exam-
ined by Western blotting (Figure 2A). In immunoblots
of different tissue extracts, the antibody to AdK detected
only two closely related protein species of molecular
masses (Mr ≈ 40-42 KDa), which correspond to the two
isoforms of AdK. In contrast to an earlier study, where
three isoforms of AdK were reported [22], no third iso-
form was detected in our study. The expression of the
two AdK isoforms varied markedly among different tis-
sues. In liver, kidney, lung and pancreas both isoforms
were expressed in comparable amounts (Figure 2A and
2B). In contrast, in heart, thymus and skeletal muscle,
expression of mainly the AdK-L isoform was observed.
Of the different tissues examined, brain was the only tis-
s u ew h e r et h es h o r ti s o f o r mw a sp r e d o m i n a n t l y
expressed (Figure 2A and 2B) [12]. The expression of
the two AdK isoforms was also examined in a number
(A)
(C)
(B)
AdK-S
AdK-L
CHO           GM7S       V79 
Figure 2 Differences in expression of two AdK isoforms in various tissues and cell lines. (A) Western blot showing the expression profile
of the two isoforms in various rat tissues; (B) Quantification of the relative amounts of two AdK isoforms in rat tissues. Expression levels of the
two isoforms were normalized relative to AdK-L level in adrenal gland and the average amount (intensity) ± SD for three independent
experiments is shown. (C) Western blot showing relative expression of the two isoforms in CH CHO, V79 and GM7S cell lines.
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lines that expressed mainly the AdK-L isoform, in the
CH V79 and GM7 cell lines derived from embryonic
lung [39], both AdK-L as well as AdK-S isoforms were
expressed (Figure 2C). The expression of the two iso-
forms was comparable in the GM7S cells, whereas in
V79 cell line the AdK-L isoform showed slightly higher
expression. In our earlier work, the human Hela cells
also showed expression of only the AdK-L isoform,
whereas in human HT-1080 cell line and mouse LM
(TK
-) cells, both AdK isoforms were expressed in com-
parable amounts [27].
Isolation and Characterization of Mutants Resistant to
Adenosine Analogs from V79 Cells
To gain insights into the cellular functions of AdK and
the regulation of its isoforms, mutants resistant to the
Ado analogs tubercidin and formycin A (FoA) were
selected from V79 cells. Of these analogs, tubercidin
(and also toyocamycin) similar to adenosine is an N-
nucleoside, whereas FoA is a C-nucleoside analog. In
our earlier work, interesting differences have been
observed in the cross-resistance patterns of AdK
mutants towards the N- and C- Ado analogs [31,34].
Under the conditions employed (see Methods section),
the resistant mutants were obtained at a frequency of ~
2.5 × 10
-7.
The degree of resistance of the mutants towards FoA
and tubercidin was determined in comparison to the
parental V79 cells. In the presence of FoA, the colony
forming ability of WT V79 or CHO cells decreased
sharply at drug concentrations between 5-10 ng/ml and
no colonies were obtained at 20 ng/ml. For tubercidin,
the colony forming ability of the WT cells decreased
sharply between 2-5 ng/ml and no colonies were
observed at 20 ng/ml. Based on these studies, the D10
values of the WT V79 cells for FoA and tubercidin were
approximated to be 10 ng/ml and 5 ng/ml, respectively
(Table 1). The degree of resistance of the mutant cell
lines in comparison to the parental sensitive cell line
was determined based on the ratios of their D10 values
[40]. Based on their relative resistance to FoA and
tubercidin, the different mutants that we have isolated
could be divided into two groups (Table 1). All four
Tub
R mutants (VT2 -5) and ten Fom
R mutants viz.
VF2-8, VF20, VF24, and VF26, which exhibited >50-fold
resistance to both FoA and tubercidin formed the first
group. The resistance levels of these mutants to these
analogs is similar to that for the toyocamycin and tuber-
cidin resistant mutant of CHO cells (including the
Toy
R-4 and DrToy
R-18) isolated previously [29,41]. In
contrast to these mutants, ten other Fom
R mutants
(VF1, VF9-13, VF15, VF18, VF19 and VF23) were
between 10-50 fold resistant to FoA, but only showed
minimal (2-5 fold) resistance to tubercidin. The drug-
resistance profile of these mutants (Group B) is similar
to that of the Fom
R-4 mutant of CHO cell isolated in
earlier work [34].
To determine if these mutants were affected in the
expression of the AdK isoforms, Western blot analysis
was performed (Figure 3). Two closely migrating protein
bands with molecular masses of ~ 40-42 kDa corre-
sponding to the two AdK isoforms were detected in the
WT V79 cells and a number of mutants (VF8, VF15,
VF18, VF19, VF20, VF24, VF26 and VT2 and VT3).
However, large differences were observed in various
Table 1 Degree of Resistance of Mutants Cell Lines to
Adenosine Analogs
V79 Cell Line Relative Resistance of the Mutant Cell lines
Formycin A Tubercidin
WT (A) 1 (~20 ng/ml) 1 (~10 ng/ml)
Tub
R2 (A) >50 >50
Tub
R3 (A) >50 >50
Tub
R4 (A) >50 >50
Tub
R5 (A) >50 >50
Fom
R2 (A) >50 >50
Fom
R3 (A) >50 >50
Fom
R4 (A) >50 >50
Fom
R5 (A) 50 >50
Fom
R6 (A) >50 >50
Fom
R7 (A) >50 >50
Fom
R8 (A) >50 >50
Fom
R20 (A) >50 >50
Fom
R24 (A) >50 >50
Fom
R26 (A) >50 >50
Fom
R1 (B) 25 2
Fom
R9 (B) 50 5
Fom
R10 (B) 50 5
Fom
R11 (B) 50 5
Fom
R12 (B) >50 5
Fom
R13 (B) 25 2
Fom
R15 (B) 50 2
Fom
R18 (B) 10 1
Fom
R19 (B) >50 2
Fom
R23 (B) 50 2
WT (CHO) 1 1
Toy
R-4 (CHO) >100 >100
DrToy
R-18 (CHO) >100 >50
Fom
R-4 (CHO) 1.5 >70
The degree of resistance of various cell lines towards formycin A and
tubercidin was determined as described in Materials and Methods. Assuming
the D10 values of these drugs for WT V79 cells as 1, the relative resistance of
the mutant cell lines was calculated. (A) and (B) refer to the two class of
mutants of V79 cells.
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forms. VF13 mutant expresses only the AdK-S isoform,
whereas in VF1-4 and VF10-12 mutants only the AdK-L
isoform was found. In contrast to these mutants, several
other mutants such as VT4, VT5, VF6, VF9 and VF23
showed no expression of either of the two AdK isoforms.
Some of the other mutants including VF18, VF19, VF24
and VF26, also showed higher expression of the AdK-S
isoform. Western blot analysis was also performed on
some of the mutants of CHO cells that are studied in this
work (Figure 3, bottom right hand panel). In the three
mutants isolated from the CHO cells, which express only
the AdK-L isoform, no cross-reactive protein was
observed in the Toy
R-4 mutant, whereas the DrToy
R-18
and Fom
R-4 mutants showed similar expression of the
AdK-L isoform as the WT cells.
The most common mechanism for resistance to Ado
analogs involves deficiency or loss of AdK activity.
Hence, AdK activity in the cell extracts of various
mutants was measured and normalized with respect to
both protein and AdK activity in the WT V79 cells. A
summary of these results is presented in Figure 4. The
cell extracts from twelve mutants (VT2-5 and VF2-4,
VF6, VF7, VF9, VF24 and VF26) contain negligible (0.5-
3%) AdK activity. The cell extracts from eleven other
mutants (VF1, VF5, VF8, VF10-13, VF15, VF20 and
VF23) contain low (6-15%), but significant level of AdK
activity (Figure 4). In contrast to these mutants that
contain either no or very low level of AdK activity, two
other mutants VF18 and VF19 contain significantly
higher amounts of AdK activity than in the WT V79
cells. The AdK activity was also examined in the three
AdK mutants of CHO cells. All three of these mutants i.
e. Toy
R-4, DrToy
R-18 and Fom
R-4 contain only back-
ground activity (i.e. ≈ 0.5 -1% of the WT level). Of these
mutants, the Toy
R-4 contains a large deletion in the
AdK gene. Hence, this level of background activity seen
i nt h ec e l le x t r a c t so fm a n ym u t a n t s( F i g u r e4 )i sn o t
due to AdK but it is possibly due to activities of other
enzymes in cell extracts [24,29,32].
Molecular Characterization of the Mutants affected in
AdK
The mutants of CHO cells lacking in AdK activity that
have been previously studied contained large deletions
in the AdK gene [32] and they provided no useful infor-
mation regarding structure-activity aspects of AdK.
With the availability of a good antibody to AdK, the
mutants lacking AdK antibody cross-reactive bands can
now be readily identified and excluded from further
analyses. These studies have revealed that the mutants
DrToy
R-18 and Fom
R-4 isolated in our earlier work
both contained normal amounts of the AdK antibody
cross-reactive bands (see Figure 3). Hence, these
mutants and two other mutants VF18 and VF19
obtained in this work were further characterized.
Of these mutants, the mutant Fom
R-4 is of particular
interest. This mutant is highly resistant to FoA and
AdK-L    
AdK-S    
AdK-L    
AdK-S    
AdK-L    
AdK-S    
AdK-L    
AdK-S    
Figure 3 Western blots showing the relative expression of the AdK-L and AdK-S short isoforms in various mutant cell lines. Equivalent
amount of cell extract (40 μg) from each of the cell lines was applied on the gels prior to electrophoresis and blotting. The WT refers to the
parental V79 cells. VF and VT refer to various mutants selected using FoA and tubercidin, respectively. The results for the CHO cells and some of
its mutant are present in the bottom right hand panel. Similar results for different mutants were obtained in at least two-independent
experiments.
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tance to various N-Ado analogs including toyocamycin
and tubercidin [31,34,41]. Interestingly, although this
mutant was able to phosphorylate adenosine and various
N-Ado analogs in vivo, the cell extracts from this
mutant showed no AdK activity and all efforts to
detect/recover AdK activity in its cell extracts have been
unsuccessful [34]. Another novel aspect of this mutant
is that its drug resistance phenotype expresses domi-
nantly in cell hybrids formed with the WT CHO cells
[34], which is in contrast to the recessive behaviour of
all other AdK
- mutants that have been studied
[29,41,42]. Hence, it was of much interest to determine
the nature of the molecular alteration in this mutant.
To characterize the molecular alterations in this and
other mutants, full-length AdK sequences from the
mutant cDNA were PCR amplified and sequenced. Of
the four independent clones from the Fom
R-4 mutant
that were sequenced, all were found to contain a single
C ® T mutation that changed a conserved Ser residue
at position 191 into phenylalanine. The changed amino
acid corresponds to position 175 in the human AdK
structure (Figure 5A) [43,44]. To confirm the signifi-
cance of this molecular alteration for the biochemical
and drug-resistance phenotype of the Fom
R-4 mutant,
the mutation causing S191 ® F alteration was intro-
duced by site-directed mutagenesis into the WT CH (or
human) AdK in the mammalian expression vector
pcDNA3.1. The WT CHO cells and an AdK
- mutant of
CHO cell (Toy
R-4) were transformed with this plasmid
DNA and stable transformants were selected in presence
of the neomycin analog G418. The degree of resistance
of these transformants as well as the WT CHO, Fom
R-4
and Toy
R-4 cell lines towards tubercidin and FoA was
determined.
The results of these experiments are shown in Figure
6. As expected, the WT CHO cells were sensitive to
both tubercidin and FoA, whereas the Toy
R-4 mutant
containing a deletion in the AdK gene was highly resis-
tant to both of them. Further, as reported in our earlier
work [34], the Fom
R-4 mutant was highly resistant to
FoA but it displayed negligible resistance to tubercidin.
The transformants obtained upon transfection of WT
cells with the AdK(S191F) plasmid were interesting since
they also exhibited resistant to FoA but were sensitive
to tubercidin. Because WT CHO cells contained normal
AdK, the FoA resistance of these transformants indi-
cated that the mutant AdK(S191F) was able to confer
resistance despite the presence of wild-type AdK. The
results obtained upon transformation of the Toy
R-4
mutant with the AdK(S191F) plasmid were equally inter-
esting. Although the Toy
R-4 mutant is highly resistant
to both tubercidin and FoA, the transformants obtained
in this case were found to be only marginally resistant
to tubercidin and they displayed similar level of resis-
tance to FoA as the Fom
R-4 mutant. These results indi-
cate that the expression of the AdK(S191F) plasmid has
made the Toy
R-4 cells sensitive towards tubercidin,
0
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Figure 4 AdK activity in the parental and mutant cell lines. The protein concentration in all cell extracts was adjusted to be the same (1
mg/ml). Assuming the AdK activity in the parental V79 cells to be 100, the relative amount (%) of AdK activity in various mutants was
determined. The results are average of at least 2 independent measurements.
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CHOFom
R-4
Ser191(175)Phe
VF18, VF19 
Leu188(172)Phe VF19 Phe221(205)Leu 
Ser191
Leu188
Phe221 Ado
(C)
(A)
DrToy
R18
Glu242(226)Lys
Glu 242
Mg
2+ Ado Asn
239
(B)
Figure 5 Molecular and Structural alterations in a number of mutants affected in AdK. (A) Partial sequence alignment of AdK from a
number of species showing the conserved residues that are altered in the Fom
R-4, VF18, VF19 and DrToy
R-18 mutants. The NxxE motif in the
sequence alignment is boxed. Of the two numbers shown for various amino acids that are altered in these mutants, the first corresponds to the
position of the amino acids in the AdK-L isoform for Chinese hamster cells, whereas the latter numbers (in parenthesis) refer to their positions in
the human AdK-S sequence, whose structure is shown below. (B) A close up view of human AdK structure [43] showing the position of the
Glu242(226) residue that is altered in the DrToy
R-18 mutant. Magnesium is shown as purple spheres and the conserved Asn239(223) and Glu242(226)
residues of the NxxE motif are shown in magenta and blue colors, respectively. The proximity of the NxxE motif to Mg
2+ and the substrate
adenosine is shown. (C) A close up view of the human AdK-S structure showing the locations of various amino acids that are altered in the
Fom
R-4, VF18 and VF19 mutants. The substrate Ado is shown in red.
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results provided strong evidence that the S191F mutation
in the AdK was behaving dominantly and it was respon-
sible for the novel genetic and biochemical properties of
the Fom
R-4 mutant.
The DrToy
R-18 mutant is highly resistant to both N-
and C- adenosine analogs. The sequencing of AdK
cDNA from this mutant revealed that it contained a sin-
gle point mutation (G ® A substitution), which changes
ac o n s e r v e dG l u 242 residue in the NxxE motif to Lys
(Figure 5A). Earlier studies indicate that the conserved
Asn and Glu residues in the NxxE motif (boxed in Fig-
ure 5A) are involved in the binding of activating phos-
phate ion, indicating that this motif is essential for AdK
function [1,45]. We have also introduced the E242K
mutation in CHO AdK cDNA in pET-15b expression
vector [45]. Upon expression, the resulting protein
showed no AdK activity (results not shown) confirming
that this mutation leads to the inactivation of the
enzyme and is responsible for the drug resistance phe-
notype of the DrToy
R18 mutant. These results provide
strong evidence that the NxxE motif is essential for
AdK function in vivo.
The AdK cDNA was also PCR sequenced from the
VF18 and VF19 mutants. For VF18 mutant, of the four
clones sequenced, 2 contained a single point mutation
changing the Leu188 into Phe. The remaining two clones
showed no change in the AdK sequence. Similarly, of the
4 clones that were sequenced from the VF19 mutant, 2
contained the same mutation (Leu188Phe) as observed in
the VF18 mutant. However, these clones in addition also
contained a second mutation changing Phe221 into Leu.
The mutant VF19 displays a higher degree of resistance
t oF o Ai nc o m p a r i s o nt ot h eV F 1 8 .T h u s ,i ti sp o s s i b l e
that these two mutations synergistically reduce the bind-
ing of FoA to AdK. The locations of various amino acids
that are altered in these mutants i.e. Ser191Phe,
Leu188Phe, Phe221Leu and Glu242Lys in the human AdK
structure are shown in Figure 5 B and 5C.
Discussion and Conclusion
This paper presents information regarding several novel
characteristics of AdK from mammalian cell lines. We
show that the two isoforms of AdK differ from each
other only in their first exons. Because each of these iso-
forms contains its own promoter, the transcription of
these two isoforms should be regulated independently at
the genetic level. The expression of the two isoforms
also differs greatly in various rat tissues. Whereas in
liver, kidney, lung and pancreas both isoforms were
expressed at comparable levels, in other tissues such as
heart, thymus, skeletal muscle and brain, either the
AdK-L or AdK-S isoform is predominantly expressed.
Large differences in the expression of these two iso-
forms have also been observed in earlier studies
[12,22,23]. Importantly, our studies also showed that the
expression of the two isoforms also differed greatly in
established cell lines. Whereas the CHO and Hela cells
expressed only the AdK-L isoform, in two other cell
lines V79 and GM7S from the same species, both AdK
isoforms were expressed in comparable amounts. It is of
interest that the V79 and GM7 cell lines, which are
d e r i v e df r o ml u n g ,e x p r e s s e s both isoforms. Therefore,
it is possible that the expression of these isoforms in
cultured cells reflect their expr e s s i o np r o f i l e si nc o r r e -
sponding tissues.
However, the main focus of this work was on isolation
and characterization of mutant CH cell lines that are
affected in AdK. From CH V79 cell line expressing both
AdK isoforms, 24 mutants resistant to FoA and tuberci-
d i nw e r ei s o l a t e d .A b o u th a l fo ft h e s em u t a n t sw e r e
highly resistant to both tubercidin and FoA, whereas the
remaining, although they were highly resistant to FoA,
(A) 
(B) 
Figure 6 Dose response curves for (A) Formycin A and (B)
tubercidin for the WT CHO (□), Fom
R-4 (●) and Toy
R-4 (▼) cell
lines and for one transformant clone selected from WT (■) and
Toy
R-4 (▲) cell lines after transfection with the expression
plasmid containing AdK(Ser191Phe) mutation. Similar results were
obtained in at least 2 independent experiments.
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Page 9 of 14exhibited only marginal resistance to tubercidin. Bio-
chemical studies have revealed that all of these mutants
except VF18 and VF19 contained either no or very low
level of AdK activity. This accounts for their resistance
to the Ado analogs, which are converted into their toxic
forms by AdK. The expression of the two AdK isoforms
in different mutants also exhibited important differ-
ences. Whereas the mutants VF6, VF9, VT4 and VT5
containing only background AdK activity lacked both
isoforms, many other mutants with similar level of AdK
activity expressed either the AdK-S isoform viz. VF13,
VF24 and VF26 or the AdK-L isoform viz. the mutants
VF1-7 and VF12. Surprisingly, the mutants VF8, VF15,
VF20 and VT2 that show negligible or greatly reduced
level of AdK activity expressed both AdK isoforms at a
level comparable to the WT V79 cells. Although, the
molecular alterations in most of these mutants remain
to be identified, it is quite likely that in mutants that do
not express either of these isoforms, mutations or dele-
tions affecting one or more of the common AdK exons
(exons 2-11) have occurred. These mutants could be
similar to the mutants CHO cells that have been pre-
viously characterized, which contained large deletions
leading to loss of several introns and exons [32,36]. In
contrast to these mutants, the mutants where expression
of either the AdK-L or AdK-S isoform is preferentially
affected are most likely to contain mutations in the pro-
moter regions for these isoforms. Thus, further molecu-
lar characterization of these mutants, such as the
methylation status, should provide useful insights con-
cerning the functional significance of the two isoforms
and how their expression may be regulated in mamma-
lian cells.
The molecular alterations in a number of mutants
resistant to Ado analogs were also identified in the pre-
sent studies. One of these mutants, DrToy
R-18 was spe-
cifically altered in the conserved NxxE motif, which has
been indicated to be important in the binding of activat-
ing phosphate ion to AdK as well as other PfkB family
of proteins [1,4,45,46]. The complete loss of AdK activ-
ity in this mutant, both in vivo and in vitro,n o wp r o -
vides direct evidence that this motif, which is in close
proximity to the binding sites for Mg
2+ ion as well the
substrate adenosine (Figure 5B), is essential for AdK
function in vivo.
In this work, we have also identified the molecular
alteration in the Fom
R-4 mutant, whose genetic and bio-
chemical characteristics have remained puzzling for >25
years. We show that this mutant contains a single base
substitution mutation that changes a conserved Ser191
into Phe. This mutation when introduced into either
CH or human AdK (results not shown) was sufficient to
confer a similar genetic and biochemical phenotype as
observed for the Fom
R-4 mutant. The Ser191Phe
mutation is present in the AdK structure [43] on the
periphery of the protein near the entrance of the sub-
strate-binding pocket (Figure 5C). The C- Ado analogs,
to whom the Fom
R-4 mutant exhibits selective resis-
tance exist predominantly in Syn conformation in con-
trast to the Anti-conformation for Ado and various N-
nucleoside analogs [31,35]. Hence, it is likely that this
molecular alteration selectively prevents the binding of
FoA and other C-nucleosides to the mutant enzyme.
However, there are two other puzzling aspects of the
Fom
R-4 mutant that remain to be addressed. First, the
cell extracts from this mutant show no AdK activity
despite its containing AdK activity in vivo. Second, the
drug-resistance phenotype of this mutant is dominant
in cell hybrids formed with WT cells [34,41]. The first
observation suggests that the reaction product of AdK
i.e. AMP is not released from the mutant enzyme
under in vitro conditions, but in the cellular milieu it
is likely directly transferred to the next enzyme AMP-
kinase (AMPK) in the pathway. The AMPK, which car-
ries out the reaction AMP + ATP ↔ 2A D P ,p l a y sa
key role in maintaining the equilibrium concentrations
of all three adenine nucleotides [47]. The subsequent
phosphorylation of ADP into ATP is carried out by the
enzyme nucleoside diphosphate kinase [48]. Because
the toxicity of Ado analogs (e.g. FoA) requires their
phosphorylation into higher phosphorylated forms (e.g.
di- and tri-phosphates), which interfere with different
metabolic pathways [31,35,49], if the mutation in AdK
prevents the conversion of FoA or FoA-PO4 into
higher phosphorylated forms then their toxicity will be
averted.
In view of these consideration, to account for the lack
of AdK activity in the Fom
R-4 extracts and the domi-
nant expression of this mutation, we postulate that the
mutant AdK and the enzyme AMPK exist as a complex
in cells such that the AMP formed from AdK reaction
is not released but directly transferred to AMPK for
conversion into ADP (Figure 7). Further, although this
complex binds adenosine, N-Ado analogs and the
monophosphates of N-adenosine analogs (i.e. Toy-MP
or Tub-MP) normally, it is unable to bind FoA or FoA-
MP as a result of the Ser191Phe mutation. The formation
of a complex between these two enzymes will explain
both the lack of AdK activity in the mutant cell extracts
(as the product AMP is not released from the mutant
enzyme) and also the dominant expression of FoA resis-
tance in this mutant. In cell hybrids formed between
WT and Fom
R-4, although the WT AdK can phosphor-
ylate FoA, the FoA-MP formed, due to its non-recogni-
tion by the AdK-AMPK complex, is not further
metabolized to higher phosphorylated forms to cause
toxic effect. Thus, these cells display resistance to FoA.
It should be noted that the Ser191Phe mutation in the
Cui et al. BMC Biochemistry 2011, 12:22
http://www.biomedcentral.com/1471-2091/12/22
Page 10 of 14Fom
R-4 mutant is present on the surface of AdK (Figure
5C) and it replaces a hydrophilic amino acid with a
hydrophobic residue thus creating a surface hydrophobic
patch (denoted by ⋆ in Figure 7) that could be impor-
tant in its complex formation with the AMPK.
Although, this model is speculative, based upon our
results, it is the only model that can account for the dif-
ferent characteristics of the Fom
R-4 mutant, which has
remained an enigma for >25 years. However, this model
makes a number of predictions, which will be experi-
mentally tested, providing further insights into the cellu-
lar function of this enzyme.
  
Ado
Tub 
FoA  Toxic
AdK(m) 
AMPK 
AdK 
AMP 
Tub-MP 
FoA-MP 
AMPK 
  ADP 
Tub-DP 
FoA-DP 
ATP 
Tub-TP 
FoA-TP 
Ado
Tub 
FoA 
ADP 
Tub-DP 
ATP 
Tub-TP  Toxic 
Ado, Tub 
AdK(m) 
AMPK 
AdK 
AMP, Tub-MP 
Ado
Tub 
FoA 
ADP 
Tub-DP 
ATP 
Tub-TP  Toxic 
FoA-MP 
FoA 
(A) Wild Type
(B) Fom
R-4 Mutant
(C) Hybrid Fom
R-4 x Wild Type
Figure 7 A model to account for the lack of AdK activity in the cell extracts of the Fom
R-4 mutant and dominant expression of its
drug-resistance phenotype. (A) In the WT cells, AdK converts Ado and various Ado-analogs (e.g. FoA, Tub) into their corresponding
monophosphates; subsequently AMP-kinase (AMPK) and other enzymes convert them into di- and tri-phosphates. (B) and (C), In the Fom
R-4
mutant or the cell hybrids formed between Fom
R-4 and the WT cells, the Ser191Phe mutation in AdK (indicated by ✭) leads to its complex
formation with AMPK. This mutation is also postulated to specifically prevent the binding of FoA and FoA-MP to the AdK-AMPK complex. As a
result of this complex formation, AMP (or Tub-MP) formed by AdK is not released but directly transferred to the AMPK for conversion into ADP.
These account for the unusual properties of the Fom
R-4 mutant.
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tions in two of the V79 cell mutants, V18 and VF19,
which similar to the Fom
R-4 mutant also exhibit prefer-
ential resistance to the C-Ado analogs. The observed
molecular alterations in these two mutants are located
on the same face of AdK as the mutation in the Fom
R-4
mutant (Figure 5C). Thus, it is likely that the genetic
changes in these mutants, Leu188Phe and Phe221Leu,
also selectively affect the binding of FoA to the mutant
AdK. However, it is of interest that of the four clones
that were sequenced for these mutants, only two con-
tained mutational alterations, whereas the other two
showed no change. This is in contrast to the Fom
R-4
mutant, where all four sequenced clones contained the
Ser191Phe mutation. Earlier work on CHO and V79 cells
has provided evidence that the CHO cell line is func-
tional hemizygous for many genetic loci including the
AdK gene, whereas in V79 cells two functional copies of
these genes were inferred [29,50]. In this context, our
observations that in the Fom
R-4 cells only the mutated
form of AdK was found, whereas in mutant V79 cells
both WT and the mutated forms of AdK were present
support to this inference. The fact that the VF18 and
VF19 mutants are resistant to FoA, despite their con-
taining normal levels of AdK activity, indicates that the
mutations in them are also expressing codominantly.
The mutants VF18 and VF19 are also of much inter-
est, because in comparison to all other AdK mutants,
they are the only mutants exhibiting enhanced AdK
activity relative to the parental V79 cells. These mutants
also show higher expression of the AdK-S isoform in
comparison to the AdK-L isoform. These observations
indicate that these mutants, in addition to the molecular
changes that we have identified in this work, also con-
tain additional genetic changes affecting the expression
of the two isoforms. To understand the functional sig-
nificance of different molecular alterations in these
mutants, it is of much interest to further characterize
AdK from these mutants at genetic, molecular and bio-
chemical levels.
Methods
Cell Culture and Cell Lines
The origins of various CH cell lines CHO, V79 and
GM7S used in this work have been described in earlier
work [29,39]. The Toy
R-4, DrToy
R-18 and Fom
R-4
mutants of CHO cells were also isolated and partially
characterized in earlier work [24,32,34]. Of these Toy
R-4
and DrToy
R-18 mutants are highly resistant to both N-
and C-Ado analogs. The mutant DrToy
R-18 was
obtained from the Dr-31 cell line, which is a different
clone of the original CHO cell line [29]. The Toy
R-4
mutant has previously been shown to contain a large
deletion in the AdK gene [24,29,32], whereas the genetic
lesion in DrToy
R-18 has not yet been identified. The
Fom
R-4 mutant was selected using FoA and its various
characteristics are described in earlier work [34,41]. The
cells were grown in monolayer culture at 37°C in alpha
medium supplemented with 5% fetal bovine serum in
95% air - 5% CO2 atmosphere. For selection of mutants,
V79 cells were treated with 300 μg/ml of the mutagen
ethyl methanesulfonate for 18 hrs and then grown for 5
days [29]. The mutants were selected by plating 5 × 10
5
cells/dish in multiple dishes in medium containing
either 200-500 ng/ml FoA (+ 10 μg/ml of the adenosine
deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl)ade-
nine) or 80 ng/ml tubercidin. The mutant colonies were
expanded and maintained by growth in non-selective
medium. The mutants were named based on the selec-
tive drug. Thus, V79Fom
R and V79Tub
R (annotated as
VF and VT) denote mutants isolated using FoA and
tubercidin. The degree of resistance of the cell lines
towards Ado analogs was determined by plating 200 and
500 cells in medium containing different concentrations
of the analogs as in earlier work [29,34]. After 7 days,
the colonies were fixed, stained with 0.5% methylene
blue and their numbers were counted. Assuming the
number of colonies formed in the absence of any drug
to be 100%, the relative plating efficiencies of cell lines
in presence of different drug concentrations were deter-
mined. The D10 value represents the drug concentration
that reduces plating efficiency of a cell line to 10% of
that observed in the absence of any drug [40]. The
sources of various Ado analogs and other chemicals
have been described in earlier work [29,34].
Adenosine kinase activity assay, Western blotting, RT-PCR
and Sequencing
AdK activity was measured as described previously using
a radioactive assay involving conversion of [
3H]-adeno-
sine to [
3H]-AMP [29,45]. [2,8-
3H]-Adenosine (40 Ci/
mmol) was purchased from American Radiolabeled Che-
micals Inc. For Western blot analysis, 40 μgo fc e l l
extracts from different cell lines were electrophoresed
on 12% sodium dodecyl sulfate polyacrylamide gels
(SDS-PAGE). After transfer to nitrocellulose and block-
ing, the blot was reacted with 1:1000 dilution of a rabbit
polyclonal antibody to human recombinant AdK raised
in our lab [27]. After washing the blot was reacted with
1:2000 dilution of anti-rabbit lgG conjugated to horse-
radish peroxidase and then developed using 4-Chloro-1-
naphthol and H2O2. All of the experiments were
repeated at least twice with very similar results. The
quantification of the results for the rat tissue experi-
ments (three independent experiments) was carried out
using the NIH ImageJ software and the average intensity
± SD was calculated. For RT-PCR, total RNA was iso-
lated from 1-2 confluent dishes using TRIzol
Cui et al. BMC Biochemistry 2011, 12:22
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Page 12 of 14(Invitrogen) as per the manufacturer’s protocol. cDNA
was generated using RevertAid™ HM i n u sF i r s tS t r a n d
c D N AS y n t h e s i sK i t s( F e r m e n t a s )w i t ho l i g o ( d T ) 1 8p r i -
mers. Full length AdK sequence was amplified from the
cDNA using the forward primer 5’-ATGGCAGCTGCT-
GAGGAGC-3’ and reverse primer 5’-TCAGTG-
GAAGTCTGGCTTCTC-3’ based on CH AdK sequence
[26]. The amplified fragments were cloned and
sequenced using the M13 forward and reverse primers.
Mammalian Cell Transfection and In vitro Mutagenesis
The full-length AdK cDNA (long isoform) from CH was
cloned in the mammalian cell expression vector
pcDNA3.1 [26]. The S191®Fm u t a t i o ni nt h eC H( o r
human) cDNA was made using the ‘Quickchange’ site-
directed mutagenesis kit (Stratagene) as described in
earlier work [27,45]. The transfection of the wild-type
(WT) or the mutant Toy
R-4 CHO cells with these plas-
mid DNAs was carried out using the Lipofectamin-2000
reagent (Invitrogen) as described in earlier work [27].
Stable transfectants expressing these genes were
obtained by growing the cells in presence of G-418 (650
μg/ml) for more than 1 month. The degree of resistance
of these transformants for tubercidin and FoA was
determined as described above.
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